160 related articles for article (PubMed ID: 19369693)
1. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
Skalli S; Desruet MD; Bourre JC; Caravel JP; Vuillez JP
Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
3. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
Serafini AN
Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
[TBL] [Abstract][Full Text] [Related]
4. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
5. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.
Lam MG; de Klerk JM; Zonnenberg BA
J Palliat Med; 2009 Jul; 12(7):649-51. PubMed ID: 19594354
[TBL] [Abstract][Full Text] [Related]
6. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I
Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
Wang RF; Zhang CL; Zhu SL; Zhu M
Med Princ Pract; 2003; 12(2):97-101. PubMed ID: 12634464
[TBL] [Abstract][Full Text] [Related]
9. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
10. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
11. [153Sm-EDTMP for moderate and severe bone cancer pain].
Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.
Dolezal J
Onkologie; 2009 Feb; 32(1-2):35-9. PubMed ID: 19209017
[TBL] [Abstract][Full Text] [Related]
13. Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
Waldert M; Klatte T; Remzi M; Sinzinger H; Kratzik C
World J Urol; 2012 Apr; 30(2):233-7. PubMed ID: 21559805
[TBL] [Abstract][Full Text] [Related]
14. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.
Tian JH; Zhang JM; Hou QT; Oyang QH; Wang JM; Luan ZS; Chuan L; He YJ
Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654
[TBL] [Abstract][Full Text] [Related]
15. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP.
Sinzinger H; Weiss K; Hiltunen J
Anticancer Res; 2009 Aug; 29(8):3393-5. PubMed ID: 19661362
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ
Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
[TBL] [Abstract][Full Text] [Related]
18. Samarium-153 lexidronam for painful bone metastases.
Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
[No Abstract] [Full Text] [Related]
19. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate].
Lovera C; Massardo T; Galleguillos MC; González P; Comparini B; Yáñez M; Fodor M; Gil MC; Araya G; Tomicic M
Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748
[TBL] [Abstract][Full Text] [Related]
20. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
Etchebehere EC; Pereira Neto CA; Lima MC; Santos Ade O; Ramos CD; Silva CM; Camargo EE
Sao Paulo Med J; 2004 Sep; 122(5):208-12. PubMed ID: 15558143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]